Basel, Switzerland-based Novartis on Friday entered into a definitive agreement to acquire Ziarco Group.
Ziarco Group is a privately held biotechnology company focused on treatments for inflammatory skin disorders.
Through the deal, Novartis will gain access to Ziarco's investigational oral treatment for moderate-to-severe eczema.
Financial details of the transaction were not disclosed.
More articles on supply chain:
McKesson, Infor form go-to-market partnership: 3 things to know
American Red Cross needs donors amid seasonal blood shortage
Amazon conducts first drone delivery to a customer